ImmuCell Corporation (ICCC)
NASDAQ: ICCC · Real-Time Price · USD
10.25
-0.19 (-1.82%)
Oct 23, 2026, 4:00 PM EDT - Market closed
ImmuCell Revenue
ImmuCell had revenue of $7.19M in the quarter ending June 30, 2026, with 11.50% growth. This brings the company's total for the last twelve months to $30.68M, up 8.49% year-over-year. In the year 2025, ImmuCell had annual revenue of $27.64M with 4.34% growth. That makes ImmuCell the 31,225th largest company in the world by revenue and 4,128th in the United States.
Revenue (ttm)
$30.68M
Revenue Growth
+8.49%
P/S Ratio
3.03
Revenue / Employee
$420,213
Employees
73
Market Cap
93.09M
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full ImmuCell breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 27.64M | 1.15M | 4.34% |
| Dec 31, 2024 | 26.49M | 9.02M | 51.64% |
| Dec 31, 2023 | 17.47M | -1.10M | -5.90% |
| Dec 31, 2022 | 18.57M | -675.01K | -3.51% |
| Dec 31, 2021 | 19.24M | 3.90M | 25.43% |
| Dec 31, 2020 | 15.34M | 1.62M | 11.80% |
| Dec 31, 2019 | 13.72M | 2.74M | 24.91% |
| Dec 31, 2018 | 10.99M | 555.21K | 5.32% |
| Dec 31, 2017 | 10.43M | 887.13K | 9.30% |
| Dec 31, 2016 | 9.54M | -684.73K | -6.69% |
| Dec 31, 2015 | 10.23M | 2.63M | 34.64% |
| Dec 31, 2014 | 7.60M | 1.59M | 26.46% |
| Dec 31, 2013 | 6.01M | 617.24K | 11.45% |
| Dec 31, 2012 | 5.39M | 278.79K | 5.45% |
| Dec 31, 2011 | 5.11M | 724.95K | 16.53% |
| Dec 31, 2010 | 4.39M | -119.56K | -2.65% |
| Dec 31, 2009 | 4.51M | -122.55K | -2.65% |
| Dec 31, 2008 | 4.63M | -6.21M | -57.31% |
| Dec 31, 2007 | 10.84M | 1.73M | 19.04% |
| Dec 31, 2006 | 9.11M | -109.26K | -1.19% |
| Dec 31, 2005 | 9.22M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Tonix Pharmaceuticals Holding | 29.10M |
| Coya Therapeutics | 8.02M |
| NeurAxis | 5.32M |
| Milestone Pharmaceuticals | 2.34M |
| Rallybio | 646.00K |
| Inovio Pharmaceuticals | 65.34K |
| Genelux | 8.00K |
ICCC News
- 13 days ago - Immucell reports preliminary Q3 revenue $8M - TheFly
- 13 days ago - ImmuCell Announces a 46% Increase in Product Sales in Quarter Three of 2026, Based on Preliminary, Unaudited Sales Results - GlobeNewsWire
- 2 months ago - ImmuCell Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - ImmuCell Earnings release: Q2 2026 - Filings
- 2 months ago - ImmuCell Quarterly report: Q2 2026 - Filings
- 2 months ago - ImmuCell Slides: Q2 2026 - Filings
- 2 months ago - ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2026 - GlobeNewsWire
- 2 months ago - ImmuCell Slides: Investor presentation - Filings